Phase 1 trial in 96 healthy European adults: Vi-CRM197+O:2-CRM197 typhoid/paratyphoid A conjugate vaccine raised no safety concerns, with no SAEs, and induced strong anti-Vi and anti-O:2 IgG responses after one dose vs control; a second dose did not boost them.
RCTn = 96
De Coster et al. Safety and immunogenicity of a conjugate vaccine candidate against Salmonella enterica serovars Typhi and Paratyphi A in healthy adults in Europe: a phase 1 randomised controlled trial